# BrainCheck

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/braincheck

- Industry: Software
- Headquarters: Austin, US
- Website: www.braincheck.com
- Total disclosed funding: $33M
- Latest round: Series A (Feb 26, 2026)
- Investors on record: 7

## About

BrainCheck, Inc. is a healthcare technology company specializing in digital neurocognitive testing and care planning, aiming to enhance cognitive health assessment and intervention across various healthcare settings. Founded in 2014 and headquartered in Houston, US, BrainCheck, Inc. focuses on digital neurocognitive assessment tools. Yael Katz, the founder, has a history in healthcare innovation. The firm has successfully completed a total of 10 deals, with the latest funding round occurring on December 21, 2023, where the company raised USD 15.367 mn from investors including Next Coast Ventures, S3 Ventures, and UPMC Enterprises. The total amount raised by the company stands at USD 15.367 mn, with a current valuation of USD 30.895 mn.BrainCheck specializes in digital neurocognitive testing and care planning, offering a comprehensive suite of tools designed to assess and monitor cognitive health. Their flagship products include BrainCheck Screen, a quick cognitive health assessment tool lasting 3-5 minutes; BrainCheck Assess, a 15-minute FDA Class II Medical Device for detecting cognitive impairment; and BrainCheck Plan, a 30-minute solution for creating personalized care plans for those diagnosed with cognitive decline. These products are integrated into healthcare systems, assisting clinicians in early detection and intervention for cognitive impairments, including Alzheimer's disease, primarily serving healthcare providers across the United States.BrainCheck operates on a reimbursement model, allowing healthcare providers to use their digital cognitive assessment tools while receiving insurance compensation for services rendered. The revenue structure is based on partnerships with healthcare organizations, offering subscriptions for their core products, including BrainCheck Screen, Assess, and Plan. Revenue is generated as clients integrate these products into their workflows, facilitating cognitive health assessments and care planning, particularly during annual wellness visits. Specific pricing details for these products are not publicly disclosed, allowing the company to maintain competitive positioning in the healthcare technology market. In February 2026, BrainCheck, Inc. raised USD 13 million in series A funding led by returning investor Next Coast Ventures, with participation from other returning investors S3 Ventures and UPMC Enterprises. The company plans to utilize the February 2026 funding for enterprise cognitive care infrastructure expansion, workflow integration, patient monitoring, population deployment, and clinical infrastructure.

## Funding rounds

- Series A, Feb 26, 2026, $13M — S3 Ventures, Next Coast Ventures, UPMC Enterprises
- Series B, Oct 3, 2021, $10M — S3 Ventures, Nueterra Capital Management, SelectQuote, Inc., Next Coast Ventures, UPMC Enterprises, True Wealth Ventures, Tensility Venture Partners
- Series A, Oct 7, 2019, $8M — S3 Ventures, Nueterra Capital Management, True Wealth Ventures, Tensility Venture Partners
- Series A, Aug 30, 2019 — True Wealth Ventures
- Seed, May 29, 2017, $1.5M — True Wealth Ventures

## Investors

- True Wealth Ventures (https://capitalatlas.ai/funds/true-wealth-ventures) — Seed, Series A, Series B
- S3 Ventures (https://capitalatlas.ai/funds/s3-ventures) — Series A, Series B
- Nueterra Capital Management (https://capitalatlas.ai/funds/nueterra-capital-management) — Series A, Series B
- Tensility Venture Partners (https://capitalatlas.ai/funds/tensility-venture-partners) — Series A, Series B
- SelectQuote, Inc. — Series B
- Next Coast Ventures (https://capitalatlas.ai/funds/next-coast-ventures) — Series B, Series A
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Series B, Series A